Novavax Announces Closing of $300 Million Offering of

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Novavax Announces Closing of $300 Million Offering of Convertible Senior Notes Due 2023

GAITHERSBURG, Md., Jan. 29, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX ), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced the closing of its previously announced offering of $300 million aggregate principal amount of convertible senior unsecured notes that will mature on February 1, 2023 (the Notes). Under the purchase agreement, the initial purchasers may exercise their option to purchase up to an additional $30 million aggregate principal amount of the Notes solely to cover over-allotments any time before February 24, 2016. The Notes were offered and sold only to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.

Citigroup and J.P. Morgan acted as joint book-running managers of the offering. Piper Jaffray and Guggenheim Securities acted as Co-Lead Managers.

The Notes bear cash interest at a rate of 3.75%, payable on February 1 and August 1 of each year, beginning on August 1, 2016. The Notes are not redeemable prior to maturity and are convertible into shares of Novavax common stock. The initial conversion rate for the Notes is 146.8213 shares of Novavax’ common stock per $1,000 principal amount of the Notes, which is equivalent to an initial conversion price of approximately $6.81 per share of Novavax’ common stock, representing an approximately 22.5% conversion premium based on the last reported sale price of Novavax’ common stock of $5.56 per share on January 25, 2016.

The net proceeds of the offering were approximately $291 million, after deducting the initial purchasers’ discounts and commissions, but prior to deducting estimated offering expenses. Novavax used approximately $34.7 million of the net proceeds from the offering to pay the cost of the previously announced capped call transactions. The cap price of the capped call transactions will be $9.73 per share, which represents a premium of approximately 75% based on the last reported sale price of Novavax’ common stock of $5.56 per share on the day of pricing, January 25, 2016, and is subject to certain adjustments under the terms of the capped call transactions.

About Novavax

Novavax, Inc. (Nasdaq: NVAX ) is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Its recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines.

Forward-Looking Statements

This press release contains forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, including, but not limited to, potential exercise by the initial purchasers of their over-allotment option and the possible effects of the capped call transactions. Each forward‐looking statement is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement. Applicable risks and uncertainties include, but are not limited to, those related to the conduct, timing and potential results from Novavax’ clinical-trials and other preclinical studies, Novavax’ plans for and potential timing of regulatory filings, the expected timing and content of regulatory actions, Novavax’ plans regarding partnering activities and business development initiatives, and the timing and success of Novavax’ commercialization, if any, of its product candidates. In addition, Novavax’ management retains broad discretion with respect to the allocation of the net proceeds of this offering. Applicable risks also include those that are listed under the heading “Risk Factors” and elsewhere in Novavax’ Annual Report on Form 10-K for the fiscal year ended December 31, 2014, in addition to the risk factors that are included from time to time in Novavax’ subsequent SEC filings. Novavax undertakes no obligation to update these forward-looking statements to reflect events or circumstances occurring after this press release. Except as otherwise noted, these forward-looking statements speak only as of the date of this press release. All forward‐looking statements are qualified in their entirety by this cautionary statement.

Contact: Novavax, Inc. Barclay A. Phillips SVP, Chief Financial Officer and Treasurer Andrea N. Flynn, Ph.D. Senior Manager, Investor Relations ir@novavax.com 240-268-2000

Scroll down for more posts ▼

Top 10 Most Recent News Articles

HVAC’s $383.6 Billion Shift Is About More Than Units

Updated Category News Views 163

Server racks are turning cooling gear into a front-row industrial story, and that deserves more attention than the usual sleepy talk about replacement air conditioners. Frost & Sullivan projects the global HVAC equipment market will reach $383.6 billion by 2031, growing at a 7.0% compound annual rate from 2025. That is a sizable market, sure, but the more interesting...

Continue Reading
PAG, HOWL and PSNL Deals Face Fresh Shareholder Checks

Updated Category News Views 38

Three proposed takeovers, three very different headaches, and one familiar question that never gets old: are regular shareholders actually receiving the best available deal? On Nov. 20, 2026, investor-rights law firm Halper Sadeh LLC said it was investigating the proposed transactions involving Penske Automotive Group, Werewolf Therapeutics and Personalis for potential...

Continue Reading
Why Dent Repair Estimates Need More Than a Simple Ruler

Updated Category News Views 60

A dent can look harmless in a parking-lot glare and still turn into a stubborn repair job once somebody examines the metal properly. That is the useful, unglamorous point Jason Phelps of Magic Dent makes in a HelloNation article: visible diameter is not a verdict. Anybody shopping for vehicle repairs, managing fleet costs, or watching the collision-service ecosystem ought...

Continue Reading
NetEase Miss Opens an Investigation, Not a Verdict

Updated Category News Views 132

A two-dollar earnings gap can make a shareholder base jumpy fast, and NetEase just handed the market a rough set of numbers to chew on. The November 19 notice says NetEase's third-quarter 2026 report missed Wall Street expectations on both earnings and revenue, followed by a sharp decline in the shares. That has prompted SueWallSt, powered by Levi & Korsinsky LLP, to...

Continue Reading
RBI Heads to Morgan Stanley With Plenty to Explain

Updated Category News Views 63

Two executives, one New York stage, and a short calendar gap give Restaurant Brands International a clean chance to address investors without the usual blizzard of quarterly slides. Chief Executive Officer Josh Kobza and Chief Financial Officer Sami Siddiqui are scheduled for a fireside chat at Morgan Stanley's Global Consumer & Retail Conference on December 2, 2026, at...

Continue Reading
Cirrus CEO Takes SIA Chair as Chip Policy Heats Up

Updated Category News Views 196

A trade-group gavel rarely moves a stock by itself, but this one lands in a noisy part of the chip cycle. On November 19, 2026, the Semiconductor Industry Association elected Cirrus Logic President and CEO John Forsyth as chair of its board. That is not a revenue announcement, not a factory groundbreaking, and certainly not a reason to start flinging confetti at...

Continue Reading
COP31 Tests Whether Climate Warnings Move Power Systems

Updated Category News Views 101

A weather alert that never reaches the control room is just expensive wallpaper. That was the useful, unsentimental thread running through a COP31 side event in Ankara on November 13: climate diplomacy is not worth much if grid operators, project owners and financiers do not change what they do when the forecast turns ugly. Implementation Means Changing Operations COP31...

Continue Reading
Dario's Personify Panel Puts Distribution Model in Focus

Updated Category News Views 208

A Partner Megaphone Is Not a Revenue Line Monday's virtual panel gives DarioHealth a useful stage, but investors should not confuse a conference microphone with a signed sales order. Erez Raphael is set to lead a November 23 discussion with Personify Health President Ed Liebowitz at the U.S. Bancorp | BTIG Tech-Enabled Healthcare Forum, running from noon to 12:50 p.m....

Continue Reading
Rock Gate Buys Aviation Niche Player Blast Deflectors

Updated Category News Views 17

Jet exhaust is not glamorous, but somebody has to keep it from battering everything nearby. Rock Gate Partners’ acquisition of Blast Deflectors, Inc. puts money behind one of those stubbornly unsexy industrial niches where engineering credibility matters far more than a flashy sales pitch. The transaction closed October 16, 2026, and Northborne Partners announced...

Continue Reading
Hope Charities Makes Care Funding Easier to Track Online

Updated Category News Views 72

A treatment bill can wreck a household long before a diagnosis does. That is the uncomfortable reality behind Hope Charities' new Access to Care website, a centralized resource meant to show people in the bleeding disorders community when diagnosis-specific charitable assistance funds are available. This is not flashy technology, nor should it be treated like some grand...

Continue Reading

Top 5 Most Recently Viewed Articles

INTCO Medical Surges Ahead with 40.6% Revenue Boost

Updated Category News Views 94

Eying Growth: INTCO Medical's Impressive Revenue Surge In today's corporate world, a 40.6% revenue jump over a single half-year isn't something to sneeze at. INTCO Medical, a heavyweight in the disposable glove industry, has done exactly that. The whispers out of Zibo, China, hint at a company that’s firing on all cylinders with $1.03 billion in their pockets for the...

Continue Reading
Taylor Davis Joins Pivot Point Consulting to Boost Client Success

Updated Category News Views 108

Pivot Point Consulting brought in a big player back then: Taylor Davis, the former President of KLAS Research. He wasn't just some guy; he founded the KLAS Arch Collaborative. This move was about shaking things up in healthcare consulting during tough times. Desks were buzzing over this power shift. In his past gig at KLAS, Davis was instrumental in creating standards...

Continue Reading
Entegris' Financial Highlights and Outlook for 2025

Updated Category News Views 971

Entegris Reports Strong Fourth Quarter Performance Entegris, Inc. (NASDAQ: ENTG) has recently released its financial results marking a robust conclusion to the fiscal year. The company's fourth-quarter performance surpassed projections for both revenue and non-GAAP earnings per share. CEO Insights on Market Dynamics Bertrand Loy, the President and CEO of Entegris,...

Continue Reading
Top Dividend Stocks Insiders Increased Their Investments In January

Updated Category News Views 109

Insider Purchasing Trends in Dividend Stocks January unveiled strong insider buying activity across various dividend-paying stocks, pointing to confidence in future growth. Leaders in this buying spree were notable companies including Lakeland Industries (NASDAQ: LAKE), York Water (NASDAQ: YORW), and RLI Corp (NYSE: RLI). Such movements may indicate these stocks are worth...

Continue Reading
FDA Approves Omvoh for Crohn's Disease: A New Era in Treatment

Updated Category News Views 515

FDA Approves Omvoh for Crohn's Disease Eli Lilly and Company (NYSE: LLY) proudly announces the FDA's approval of Omvoh (mirikizumab-mrkz), a groundbreaking treatment for adults suffering from moderately to severely active Crohn's disease. This marks a significant advancement, as Omvoh is now recognized for treating not just this debilitating condition but also ulcerative...

Continue Reading